Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
Keros Therapeutics, Inc. - common stock (KROS)
Company Research
Source: GlobeNewswire
LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”), today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Guggenheim Healthcare Innovation Conference on Wednesday, November 13, 2024 at 3:30 p.m. Eastern time. A live audio webcast of the fireside chat presentation will be available at https://wsw.com/webcast/guggen/kros/1967811 and an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of the event. About Keros Therapeutics, Inc.Keros is a clinical-stage biopharmaceutical company focused
Show less
Read more
Impact Snapshot
Event Time:
KROS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KROS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KROS alerts
High impacting Keros Therapeutics, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
KROS
News
- Keros Therapeutics, Inc. (NASDAQ: KROS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $84.00 price target on the stock.MarketBeat
- Keros Therapeutics, Inc. (NASDAQ: KROS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.MarketBeat
- Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial ResultsGlobeNewswire
- Keros Therapeutics, Inc. (NASDAQ: KROS) was upgraded by analysts at Wedbush to a "strong-buy" rating.MarketBeat
KROS
Earnings
- 11/6/24 - Miss
KROS
Sec Filings
- 11/12/24 - Form 4
- 11/8/24 - Form 3
- 11/6/24 - Form 10-Q
- KROS's page on the SEC website